Twitter
  • Business case
    • The migraine market
    • The market for rhinitis
    • Neuromodulation
    • The CEO about the future
    • Our patents
    • Our history
    • Partners
  • Clinical benefits
    • Migraine
    • Rhinitis
    • How K.O.S is used
    • Positive indications – studies and publications
  • News
  • Investor relations
    • Press releases
    • Financial reports
    • Equity research & presentations
    • Financial calendar
    • The share
    • Corporate Governance
    • Company description
    • Owner information
    • Rights Issue 2022
  • FAQ
  • Svenska
Menu
  • Business case
    • The migraine market
    • The market for rhinitis
    • Neuromodulation
    • The CEO about the future
    • Our patents
    • Our history
    • Partners
  • Clinical benefits
    • Migraine
    • Rhinitis
    • How K.O.S is used
    • Positive indications – studies and publications
  • News
  • Investor relations
    • Press releases
    • Financial reports
    • Equity research & presentations
    • Financial calendar
    • The share
    • Corporate Governance
    • Company description
    • Owner information
    • Rights Issue 2022
  • FAQ
  • Svenska

Category: Uncategorized

  • Uncategorized

    New Italian study shows that K.O.S has positive effects on allergic rhinitis

  • Uncategorized

    Chordate Medical’s two incentive programs fully subscribed by the board and management

  • Uncategorized

    Chordate Medical Holding (publ) Interim Report January-March 2023

  • Uncategorized

    Chordate Medical presents interim report for Q1 2023

  • Uncategorized

    Biostock: The market in Saudi Arabia opens up for Chordate

  • Uncategorized

    NHS gives ethical approval for Chordate’s new migraine study

  • Uncategorized

    Chordate’s market in Saudi Arabia – position and potential

  • Uncategorized

    Chordate Medical receives rhinitis-order from private hospital chain in Jeddah

  • Uncategorized

    Interview: specialist in neurology dr. Emilia Tauriala on Chordate’s migraine treatment

  • Uncategorized

    Biostock: Chordate presents study results for the American Headache SocietyBiostock:

1 2 3 … 8

Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel and Saudi Arabia. Chordate Medical’s share is listed on the Nasdaq First North Growth Market (ticker: CMH).

Press releases

New Italian study shows that K.O.S has positive effects on allergic rhinitis

29 May 2023

Chordate Medical’s two incentive programs fully subscribed by the board and management

26 May 2023

Chordate Medical Holding (publ) Interim Report January-March 2023

25 May 2023

Chordate Medical AB

c/o Regus, Kistagången 20B
SE-164 40 Kista
Sweden

Privacy policy

Twitter
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
SAVE & ACCEPT